Streptococcus pneumoniae DNA Gyrase and Topoisomerase IV: Overexpression, Purification, and Differential Inhibition by Fluoroquinolones
- 1 May 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (5) , 1129-1136
- https://doi.org/10.1128/aac.43.5.1129
Abstract
Streptococcus pneumoniae gyrA and gyrB genes specifying the DNA gyrase subunits have been cloned into pET plasmid vectors under the control of an inducible T7 promoter and have been separately expressed in Escherichia coli . Soluble 97-kDa GyrA and 72-kDa GyrB proteins bearing polyhistidine tags at their respective C-terminal and N-terminal ends were purified to apparent homogeneity by one-step nickel chelate column chromatography and were free of host E. coli topoisomerase activity. Equimolar amounts of the gyrase subunits reconstituted ATP-dependent DNA supercoiling with comparable activity to gyrase of E. coli and Staphylococcus aureus . In parallel, S. pneumoniae topoisomerase IV ParC and ParE subunits were similarly expressed in E. coli , purified to near homogeneity as 93- and 73-kDa proteins, and shown to generate efficient ATP-dependent DNA relaxation and DNA decatenation activities. Using the purified enzymes, we examined the inhibitory effects of three paradigm fluoroquinolones—ciprofloxacin, sparfloxacin, and clinafloxacin—which previous genetic studies with S. pneumoniae suggested act preferentially through topoisomerase IV, through gyrase, and through both enzymes, respectively. Surprisingly, all three quinolones were more active in inhibiting purified topoisomerase IV than gyrase, with clinafloxacin showing the greatest inhibitory potency. Moreover, the tested agents were at least 25-fold more effective in stabilizing a cleavable complex (the relevant cytotoxic lesion) with topoisomerase IV than with gyrase, with clinafloxacin some 10- to 32-fold more potent against either enzyme, in line with its superior activity against S. pneumoniae . The uniform target preference of the three fluoroquinolones for topoisomerase IV in vitro is in apparent contrast to the genetic data. We interpret these results in terms of a model for bacterial killing by quinolones in which cellular factors can modulate the effects of target affinity to determine the cytotoxic pathway.Keywords
This publication has 32 references indexed in Scilit:
- Community-Acquired PneumoniaNew England Journal of Medicine, 1995
- Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli.Genes & Development, 1995
- The Pneumococcus at the GatesNew England Journal of Medicine, 1995
- The Prevalence of Drug-ResistantStreptococcus pneumoniaeIn AtlantaNew England Journal of Medicine, 1995
- Resistance to Penicillin and Cephalosporin and Mortality from Severe Pneumococcal Pneumonia in Barcelona, SpainNew England Journal of Medicine, 1995
- Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolonesMolecular Microbiology, 1994
- The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replicationCell, 1992
- Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coliAntimicrobial Agents and Chemotherapy, 1991
- New topoisomerase essential for chromosome segregation in E. coliCell, 1990
- Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coliAntimicrobial Agents and Chemotherapy, 1990